peg mgf and igf-1 lr3 cycle Schematic representation of the TG/FFA cycle. Within adipocytes, TG is IGF-1 LR3 for Muscle Growth:

The goal is to reduce the physiological work required to neutralize and eliminate organic acids, support renal handling of metabolic waste and improve the biochemical terrain in which adenosine, homocysteine and SAH are managed

\Improved Glucose Regulation: Insulinotropic effects of Retatrutide + glucagon suppression from Cagrilintide

Free from gluten, dairy, soy, and magnesium stearate, this product is made with carefully selected ingredients to meet high-quality standards

Many of the bees bodies are lost, leading to death

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono